Bouck N - Search Results

1

c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1.

Jiménez B, Volpert OV, Reiher F, Chang L, Muñoz A, Karin M, Bouck N. Jiménez B, et al. Among authors: bouck n. Oncogene. 2001 Jun 7;20(26):3443-8. doi: 10.1038/sj.onc.1204464. Oncogene. 2001. PMID: 11423995

2

Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.

Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, Haviv F, Bouck NP, Campbell SC. Reiher FK, et al. Among authors: bouck np. Int J Cancer. 2002 Apr 10;98(5):682-9. doi: 10.1002/ijc.10247. Int J Cancer. 2002. PMID: 11920636

3

A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1.

Volpert OV, Lawler J, Bouck NP. Volpert OV, et al. Among authors: bouck np. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6343-8. doi: 10.1073/pnas.95.11.6343. Proc Natl Acad Sci U S A. 1998. PMID: 9600967 Free PMC article.

4

Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate.

Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP. Doll JA, et al. Among authors: bouck np. Prostate. 2001 Dec 1;49(4):293-305. doi: 10.1002/pros.10025. Prostate. 2001. PMID: 11746276

5

Inhibition of angiogenesis by thrombospondin-2.

Volpert OV, Tolsma SS, Pellerin S, Feige JJ, Chen H, Mosher DF, Bouck N. Volpert OV, et al. Among authors: bouck n. Biochem Biophys Res Commun. 1995 Dec 5;217(1):326-32. doi: 10.1006/bbrc.1995.2780. Biochem Biophys Res Commun. 1995. PMID: 8526929

6

Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity.

Volpert OV, Dameron KM, Bouck N. Volpert OV, et al. Among authors: bouck n. Oncogene. 1997 Mar 27;14(12):1495-502. doi: 10.1038/sj.onc.1200977. Oncogene. 1997. PMID: 9136993

7

Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1.

Jiménez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Jiménez B, et al. Among authors: bouck n. Nat Med. 2000 Jan;6(1):41-8. doi: 10.1038/71517. Nat Med. 2000. PMID: 10613822

8

In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects.

Filleur S, Volpert OV, Degeorges A, Voland C, Reiher F, Clézardin P, Bouck N, Cabon F. Filleur S, et al. Among authors: bouck n. Genes Dev. 2001 Jun 1;15(11):1373-82. doi: 10.1101/gad.193501. Genes Dev. 2001. PMID: 11390357 Free PMC article.

9

Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat.

Dawson DW, Volpert OV, Pearce SF, Schneider AJ, Silverstein RL, Henkin J, Bouck NP. Dawson DW, et al. Among authors: bouck np. Mol Pharmacol. 1999 Feb;55(2):332-8. doi: 10.1124/mol.55.2.332. Mol Pharmacol. 1999. PMID: 9927626

10

Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor.

Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP. Volpert OV, et al. Among authors: bouck np. Nat Med. 2002 Apr;8(4):349-57. doi: 10.1038/nm0402-349. Nat Med. 2002. PMID: 11927940

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89 results

Search Page

Filters